Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) Research & Development (2016 - 2025)

Alterity Therapeutics has reported Research & Development over the past 4 years, most recently at -$4.2 million for Q4 2018.

  • For Q4 2018, Research & Development fell 140.33% year-over-year to -$4.2 million; the TTM value through Dec 2018 reached -$10.2 million, changed N/A, while the annual FY2025 figure was $9.3 million, 23.65% down from the prior year.
  • Research & Development for Q4 2018 was -$4.2 million at Alterity Therapeutics, down from -$1.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $2.9 million in Q4 2016 and troughed at -$7.1 million in Q4 2015.
  • A 4-year average of -$2.5 million and a median of -$3.0 million in 2018 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 140.61% in 2016 and later plummeted 161.16% in 2017.
  • Year by year, Research & Development stood at -$7.1 million in 2015, then soared by 140.61% to $2.9 million in 2016, then tumbled by 161.16% to -$1.8 million in 2017, then crashed by 140.33% to -$4.2 million in 2018.
  • Business Quant data shows Research & Development for ATHE at -$4.2 million in Q4 2018, -$1.8 million in Q4 2017, and $2.9 million in Q4 2016.